Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 15/20 | 0.65 |
| ▸ | KIT | P10721 | 11/20 | 0.65 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137188 | 1.00 | KDR (0.65) | KDRPDGFRBKITFLT3FGFR1 | |
| SCHEMBL153793 | 0.99 | KDR (0.66) | KDRPDGFRBKITFLT3FGFR1 | |
| SCHEMBL139994 | 0.99 | KDR (0.66) | KDRPDGFRBKITFLT3FGFR1 | |
| SCHEMBL168723 | 0.94 | PDGFRB (0.67) | KDRPDGFRBKITFLT3FGFR1 | |
| SCHEMBL138701 | 0.94 | PDGFRB (0.67) | KDRPDGFRBKITFLT3FGFR1 | |
| SCHEMBL151719 | 0.89 | KDR (0.65) | KDRPDGFRBKITFLT3FGFR1 | |
| SCHEMBL137190 | 0.89 | KDR (0.65) | KDRPDGFRBKITFLT3FGFR1 | |
| SCHEMBL137179 | 0.89 | PDGFRB (0.67) | KDRPDGFRBKITFLT3FGFR1 | |
| SCHEMBL156392 | 0.89 | PDGFRB (0.67) | KDRPDGFRBKITFLT3FGFR1 | |
| SCHEMBL154331 | 0.89 | PDGFRB (0.69) | KDRPDGFRBKITFLT3FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973910-B1 | PYRROLO[3,2-C]PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2013-06-26 | — | — | EP | claimed |
| US-20100004239-A1 | Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2010-01-07 | — | — | US | claimed |
| US-8697692-B2 | Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2014-04-15 | — | — | US | disclosed |
| EP-1973910-B1 | PYRROLO[3,2-C]PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2013-06-26 | — | — | EP | disclosed |
| US-8362251-B2 | Pyrrolo [3,2-C] pyridine-4-one 2-indolinone protein kinase inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-01-29 | — | — | US | disclosed |
| US-20120058107-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-03-08 | — | — | US | disclosed |
| US-20110301353-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2011-12-08 | — | — | US | disclosed |
| US-8012966-B2 | Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2011-09-06 | — | — | US | disclosed |
| US-20100004239-A1 | Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2010-01-07 | — | — | US | disclosed |
| EP-1973910-A1 | PYRROLO Ý3,2-C¨PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007085188-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058107-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | DMPK, PDPK1, PRKAR2A | KDR 1027/4885PDGFRB 657/4885KIT 456/4885 |
| US-20110301353-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | DMPK, PDPK1, PRKAR2A | KDR 1027/4885PDGFRB 657/4885KIT 456/4885 |
| US-20100004239-A1 | Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors | DMPK, CDK2, PRKAR2A | KDR 780/4885PDGFRB 547/4885KIT 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.